Description
Book SynopsisSquamous cell cancers of the head and neck (SCCHN), also known as head and neck cancers (HNC) encompass malignancies of the oral cavity, larynx, nasopharynx and pharynx, and are diagnosed in over 500,000 patients worldwide each year, accounting for 5% of all malignancies. It is estimated that approximately 50,000 patients develop head and neck cancer annually in the United States, of whom approximately 50% succumb to this cancer. For most cases of SCCHN, treatment is multimodal, often combining surgery or irradiation with chemotherapy; even successfully treated patients frequently experience durable and severe side effects. Improving cure rates and reducing chronic morbidity are urgent clinical needs for head and neck cancer. However, in contrast to cancer types such as breast or prostate that have been much studied and have well-defined biology, until recently, relatively few researchers investigated the molecular basis of HNC, making it difficult to design targeted treatments with better efficacy and less debilitating side effects.
This volume will provide an overview of the factors contributing to disease pathogenesis, including the recognition of discrete molecular subtypes with distinct etiology, prognosis, and treatment response. This volume will familiarize the reader with the critical signaling pathways and oncogenic drivers for HNC. It will outline the differences between HPV-positive and HPV-negative disease, and how these differences affect treatment choice and outcome. The book will emphasize developments in the past five years, including the growing understanding of the genomic and epigenomic features of the disease based on analysis of next generation sequencing (NGS) data, and timely topics such as the analysis of HNC stem cell populations, non-coding mRNAs, and inflammatory response. It will address exciting new therapeutic approaches such as the use of immunotherapies to treat HNC patients. Overall, the book will provide the reader with current understanding of the biology and treatment of the disease, and describe timely questions that will guide future research aimed at controlling and curing this disease.
Trade Review“The book is intended primarily for clinicians, fellows, interns, and trainees, but medical students who may be interested in head and neck cancer but face the challenge of updating themselves on the latest innovations may also find this book very useful. … this is an informative and authoritative book on the subject that includes experiences from clinicians and scientists working on head and neck cancer at some of the most renowned cancer centers in the world.” (Ravi Salgia, Doody's Book Reviews, March, 2019)
Table of ContentsChapter 1: Overview: B. Burtness and E. Golemis
Chapter 2: HER inhibition in HNC: E. Golemis and B. Burtness
Chapter 3: MET: T Beck, Fox Chase Cancer Center
Chapter 4: PI3K/mTOR/AMPK: C. Chung, Moffit Cancer Center
Chapter 5: Jak/STAT: J.R. Grandis, UCSF
Chapter 6: TGFb: Neiman and Wang, University of Colorado
Chapter 7: Wnt and catenin Signaling: MA Kukurusinska, Boston University
Chapter 8: P53/p63/p73: B. Burtness
Chapter 9: DNA damage: R. Bindra, Yale University
Chapter 10: APOBEC Proteins: K.S. Anderson, Yale University
Chapter 11: Hypoxia, including HIF1: Q. Le, Stanford University
Chapter 12: VEGF/Angiogenesis and Antiangiogenic Therapy: A Argiris, Thomas Jefferson University
Chapter 13: Sequencing/genomic insights: J.Myers, MD Anderson
Chapter 14: Gene expression, Methylation, and histones: R.Mehra, A.Andrews, S.Peri, Fox Chase Cancer Center and A.Bhatia, Yale University
Chapter 15: Inflammation: Carter Van Waes, NIH
Chapter 16:Immunotherapy: Ferris and Baumann, UPMC
Chapter 17: FAK/Integrin pathway inhibitors: Nils Cordes, Dresden
Chapter 18: Targeting cell cycle controls: E.Golemis
Chapter 19: Head and neck cancer stem cells: L.Bourguignon, UCSF
Chapter 20: Non-coding RNAs: C.Punyadeera, Queensland University
Chapter 21: Epidemiology of HPV: Ragin and Lui, Fox Chase Cancer Center
Chapter 22: DNA damage in HPV-positive SCCHN: WG Yarbrough, Yale University
Chapter 23: Treatment paradigms in HPV-positive SCCHN: A Cmelak, Vanderbilt University
